## Michael M Ward

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8070709/publications.pdf

Version: 2024-02-01

180 papers 11,489 citations

<sup>38742</sup> 50 h-index

30922 102 g-index

181 all docs

181 docs citations

times ranked

181

10291 citing authors

#	Article	IF	CITATIONS
1	Response to: †Correspondence on †EULAR recommendations for the management of antiphospholipid syndrome in adults†M†by Gao and Qin. Annals of the Rheumatic Diseases, 2023, 82, e107-e107.	0.9	1
2	Response to: †Correspondence on †EULAR recommendations for the management of antiphospholipid syndrome in adults†by Zhou <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e249-e249.	0.9	3
3	Trends in Permanent Work Disability Associated With Rheumatoid Arthritis in the United States, 1999–2015. Arthritis Care and Research, 2022, 74, 1321-1324.	3.4	2
4	Estimates of minimal clinically important improvments vary with the responsiveness of the sample. Journal of Clinical Epidemiology, 2022, 142, 110-118.	5.0	1
5	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases, 2022, 81, 768-779.	0.9	128
6	Vertebral Bone Mineral Density, Vertebral Strength, and Syndesmophyte Growth in Ankylosing Spondylitis: The Importance of Bridging. Arthritis and Rheumatology, 2022, 74, 1352-1362.	5.6	6
7	Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Network Open, 2022, 5, e222312.	5.9	10
8	Sacroiliac Bone Marrow Edema: Innocent Until Proven Guilty?. Arthritis and Rheumatology, 2022, 74, 1474-1476.	5.6	1
9	Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. Rheumatology, 2021, 60, 2134-2145.	1.9	9
10	Accuracy of diagnoses of inflammatory arthritis in administrative hospitalization databases. Pharmacoepidemiology and Drug Safety, 2021, 30, 257-265.	1.9	1
11	Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2021, 80, 1168-1174.	0.9	49
12	Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis. ACR Open Rheumatology, 2021, 3, 413-421.	2.1	0
13	Osteoarthritis care and risk of total knee arthroplasty among medicare beneficiaries. Arthritis and Rheumatology, 2021, 73, 2261-2270.	5.6	8
14	Risk of 30-day Readmission after Knee or Hip Replacement in Rheumatoid Arthritis and Osteoarthritis by non-Medicare and Medicare Payer Status. Journal of Rheumatology, 2021, , jrheum.201370.	2.0	0
15	Regional Variation in Surgical Procedure Rates. JAMA Surgery, 2021, , .	4.3	4
16	The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort. Journal of Rheumatology, 2021, , jrheum.210332.	2.0	3
17	Nonsteroidal Antiinflammatory Drugs as Potential Diseaseâ€Modifying Medications in Axial Spondyloarthritis. Arthritis and Rheumatology, 2020, 72, 518-528.	5.6	13
18	Chronic oral anticoagluation and risk of prostate cancer: Evidence of detection bias. International Journal of Cancer, 2020, 146, 3022-3025.	5.1	1

#	Article	IF	Citations
19	Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. Arthritis Care and Research, 2020, 72, 1645-1652.	3.4	21
20	Regional Variation in Rates of Total Knee Arthroplasty Among Medicare Beneficiaries. JAMA Network Open, 2020, 3, e203717.	5.9	18
21	Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis. Rheumatology, 2020, 59, 3917-3926.	1.9	2
22	Belimumab as Add-on Therapy in Lupus Nephritis. New England Journal of Medicine, 2020, 383, 1184-1185.	27.0	13
23	Genomewide Association Study of Acute Anterior Uveitis Identifies New Susceptibility Loci., 2020, 61, 3.		43
24	Racial/Ethnic Differences in Dialysis Discontinuation and Survival after Hospitalization for Serious Conditions among Patients on Maintenance Dialysis. Journal of the American Society of Nephrology: JASN, 2020, 31, 149-160.	6.1	10
25	Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort. Rheumatology International, 2020, 40, 1053-1061.	3.0	8
26	The changing profile of ankylosing spondylitis in the biologic era. Clinical Rheumatology, 2020, 39, 2641-2651.	2.2	3
27	Risks of solid cancers in elderly persons with osteoarthritis or ankylosing spondylitis. Rheumatology, 2020, 59, 3817-3825.	1.9	13
28	Increased Rates of Both Knee and Hip Arthroplasties in Older Patients with Ankylosing Spondylitis. Journal of Rheumatology, 2019, 46, 31-37.	2.0	14
29	2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care and Research, 2019. 71. 1285-1299.	3.4	274
30	2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2019, 71, 1599-1613.	5.6	401
31	Validity of health transition questions is supported by larger clinical improvements in purposive samples enriched for improvers. Journal of Clinical Epidemiology, 2019, 116, 138-139.	5.0	1
32	Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open, 2019, 5, e000924.	3.8	52
33	EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases, 2019, 78, 1296-1304.	0.9	664
34	Interhospital variation in mortality among patients with systemic lupus erythematosus and sepsis in the USA. Rheumatology, 2019, 58, 1794-1801.	1.9	12
35	Aortic-vertebral interaction in ankylosing spondylitis: syndesmophyte development at the juxta-aortic vertebral rim. Annals of the Rheumatic Diseases, 2019, 78, 922-928.	0.9	6
36	Socioeconomic and Disability Aspects. , 2019, , 759-769.		1

#	Article	IF	CITATIONS
37	Translating Treatment Effects Between Rheumatoid Arthritis Activity Measures and American College of Rheumatology Responses in Direct Comparison Trials. Arthritis Care and Research, 2019, 71, 1482-1487.	3.4	1
38	HLA class I and II alleles in susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2019, 78, 66-73.	0.9	52
39	Minimal Clinically Important Improvement of Routine Assessment of Patient Index Data 3 in Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 27-30.	2.0	20
40	Complications of Total Hip Arthroplasty in Patients With Ankylosing Spondylitis. Arthritis Care and Research, 2019, 71, 1101-1108.	3.4	17
41	Origins of Discordant Responses among 3 Rheumatoid Arthritis Improvement Criteria. Journal of Rheumatology, 2018, 45, 745-752.	2.0	1
42	Comparative Efficacy of Tumor Necrosis Factor-α Inhibitors in Ankylosing Spondylitis: A Systematic Review and Bayesian Network Metaanalysis. Journal of Rheumatology, 2018, 45, 481-490.	2.0	19
43	Feasibility and assessment of outcome measures for yoga as self-care for minorities with arthritis: a pilot study. Pilot and Feasibility Studies, 2018, 4, 53.	1,2	7
44	Computed tomography in axial spondyloarthritis. Current Opinion in Rheumatology, 2018, 30, 334-339.	4.3	17
45	Medications received by patients with juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 513-522.	3.4	16
46	Epidemiology of axial spondyloarthritis: an update. Current Opinion in Rheumatology, 2018, 30, 137-143.	4.3	126
47	Opioid Analgesic Use in Patients with Ankylosing Spondylitis: An Analysis of the Prospective Study of Outcomes in an Ankylosing Spondylitis Cohort. Journal of Rheumatology, 2018, 45, 188-194.	2.0	20
48	Better Quantification of Syndesmophyte Growth in Axial Spondyloarthritis. Current Rheumatology Reports, 2018, 20, 46.	4.7	5
49	Testing the construct validity of a health transition question using vignette-guided patient ratings of health. Health and Quality of Life Outcomes, 2018, 16, 2.	2.4	4
50	Risk of total knee arthroplasty in young and middle-aged adults with ankylosing spondylitis. Clinical Rheumatology, 2018, 37, 3431-3433.	2.2	7
51	Endogenous oscillatory activity modulates category tuning in ventral temporal cortex. Journal of Vision, 2018, 18, 553.	0.3	0
52	Direct and Indirect Determinants of the Patient Global Assessment in Rheumatoid Arthritis: Differences by Level of Disease Activity. Arthritis Care and Research, 2017, 69, 323-329.	3.4	25
53	Methodological Quality of Studies of Endstage Renal Disease in Lupus Nephritis, 1970 to 2015. Journal of Rheumatology, 2017, 44, 626-630.	2.0	0
54	Zygapophyseal Joint Fusion in Ankylosing Spondylitis Assessed by Computed Tomography: Associations with Syndesmophytes and Spinal Motion. Journal of Rheumatology, 2017, 44, 1004-1010.	2.0	22

#	Article	IF	CITATIONS
55	Screening for depression in arthritis populations: an assessment of differential item functioning in three self-reported questionnaires. Quality of Life Research, 2017, 26, 2507-2517.	3.1	6
56	A qualitative approach exploring the acceptability of yoga for minorities living with arthritis: †Where are the people who look like me?'. Complementary Therapies in Medicine, 2017, 31, 82-89.	2.7	23
57	Thoracic Syndesmophytes Commonly Occur in the Absence of Lumbar Syndesmophytes in Ankylosing Spondylitis: A Computed Tomography Study. Journal of Rheumatology, 2017, 44, 1828-1832.	2.0	10
58	Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Annals of the Rheumatic Diseases, 2017, 76, 2009-2016.	0.9	155
59	Applicability of patient utilities as measures of overall quality of life in rheumatoid arthritis clinical trials. Rheumatology, 2017, 56, 239-246.	1.9	2
60	Standards of Comparison and Discordance in Rheumatoid Arthritis Global Assessments Between Patients and Clinicians. Arthritis Care and Research, 2017, 69, 1260-1265.	3.4	8
61	Neurodynamics of expression coding in human fusiform. Journal of Vision, 2017, 17, 821.	0.3	0
62	Progression of Nonradiographic Axial Spondyloarthritis to Ankylosing Spondylitis: A Populationâ€Based Cohort Study. Arthritis and Rheumatology, 2016, 68, 1415-1421.	5.6	58
63	Brief Report: Trends in Hospitalizations Due to Acute Coronary Syndromes and Stroke in Patients With Systemic Lupus Erythematosus, 1996 to 2012. Arthritis and Rheumatology, 2016, 68, 2680-2685.	5.6	43
64	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care and Research, 2016, 68, 151-166.	3.4	53
65	American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis and Rheumatology, 2016, 68, 282-298.	5.6	383
66	Risk of Endâ€Stage Renal Disease in Patients With Lupus Nephritis, 1971–2015: A Systematic Review and Bayesian Metaâ€Analysis. Arthritis and Rheumatology, 2016, 68, 1432-1441.	5.6	352
67	Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim. Annals of the Rheumatic Diseases, 2016, 75, 1951-1957.	0.9	17
68	Measures of Arthritis Activity Associated With Patientâ€Reported Improvement in Rheumatoid Arthritis When Assessed Prospectively Versus Retrospectively. Arthritis Care and Research, 2015, 67, 776-781.	3.4	5
69	Syndesmophyte growth in ankylosing spondylitis. Current Opinion in Rheumatology, 2015, 27, 326-332.	4.3	42
70	Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2â€years. Annals of the Rheumatic Diseases, 2015, 74, 437-443.	0.9	31
71	Domain-specific transition questions demonstrated higher validity than global transition questions as anchors for clinically important improvement. Journal of Clinical Epidemiology, 2015, 68, 655-661.	5.0	26
72	Public knowledge of automatic external defibrillators in a large U.S. urban community. Resuscitation, 2015, 92, 101-106.	3.0	37

#	Article	IF	CITATIONS
73	Burden of Serious Infections in Adults With Systemic Lupus Erythematosus: A National Populationâ€Based Study, 1996–2011. Arthritis Care and Research, 2015, 67, 1078-1085.	3.4	138
74	Quantitation of Circumferential Syndesmophyte Height along the Vertebral Rim in Ankylosing Spondylitis Using Computed Tomography. Journal of Rheumatology, 2015, 42, 472-478.	2.0	9
75	Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Annals of the Rheumatic Diseases, 2015, 74, 1691-1696.	0.9	79
76	Dynamics of syndesmophyte growth in AS as measured by quantitative CT: heterogeneity within and among vertebral disc spaces. Rheumatology, 2015, 54, 972-980.	1.9	7
77	Time Perspective and Exercise, Obesity, and Smoking: Moderation of Associations by Age. American Journal of Health Promotion, 2014, 29, 9-16.	1.7	21
78	Clinically Important Changes in Short Form 36 Health Survey Scales for Use in Rheumatoid Arthritis Clinical Trials: The Impact of Low Responsiveness. Arthritis Care and Research, 2014, 66, 1783-1789.	3.4	70
79	Brief Report: Rheumatoid Arthritis Response Criteria and Patientâ€Reported Improvement in Arthritis Activity: Is an American College of Rheumatology Twenty Percent Response Meaningful to Patients?. Arthritis and Rheumatology, 2014, 66, 2339-2343.	5.6	30
80	Quality of Care for Incident Lupus Nephritis Among Medicaid Beneficiaries in the United States. Arthritis Care and Research, 2014, 66, 617-624.	3.4	44
81	Dependence of the minimal clinically important improvement on the baseline value is a consequence of floor and ceiling effects and not different expectations by patients. Journal of Clinical Epidemiology, 2014, 67, 689-696.	<b>5.</b> 0	22
82	Thirtyâ€Day Hospital Readmissions in Systemic Lupus Erythematosus: Predictors and Hospital―and Stateâ€Level Variation. Arthritis and Rheumatology, 2014, 66, 2828-2836.	5.6	54
83	MICA, a gene contributing strong susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases, 2014, 73, 1552-1557.	0.9	47
84	Quantitative measurement of syndesmophyte volume and height in ankylosing spondylitis using CT. Annals of the Rheumatic Diseases, 2014, 73, 544-550.	0.9	31
85	Update on the American College of Rheumatology/Spondyloarthritis Research and Treatment Network/Spondylitis Association of America axial spondyloarhtritis treatment guidelines project. Clinical Rheumatology, 2014, 33, 739-740.	2.2	2
86	Time perspective and medication adherence among individuals with hypertension or diabetes mellitus. Patient Education and Counseling, 2014, 95, 104-110.	2.2	30
87	Recent Clinical Trials in Lupus Nephritis. Rheumatic Disease Clinics of North America, 2014, 40, 519-535.	1.9	9
88	A pilot study of yoga as self-care for arthritis in minority communities. Health and Quality of Life Outcomes, 2013, 11, 55.	2.4	18
89	The Impact of Tumor Necrosis Factor α Inhibitors on Radiographic Progression in Ankylosing Spondylitis. Arthritis and Rheumatism, 2013, 65, 2645-2654.	6.7	391
90	Sense of Control and Self-Reported Health in a Population-Based Sample of Older Americans: Assessment of Potential Confounding by Affect, Personality, and Social Support. International Journal of Behavioral Medicine, 2013, 20, 140-147.	1.7	39

#	Article	IF	CITATIONS
91	Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: Differences in early and late disease. Arthritis Care and Research, 2013, 65, 257-265.	3.4	23
92	Time Perspective and Smoking, Obesity, and Exercise in a Community Sample. American Journal of Health Behavior, 2013, 37, 171-180.	1.4	26
93	Functional Limitations Due to Axial and Peripheral Joint Impairments in Patients With Ankylosing Spondylitis: Are Focused Measures More Informative?. Arthritis Care and Research, 2013, 65, 607-614.	3.4	9
94	Parental educational attainment and sense of control in mid- and late-adulthood Developmental Psychology, 2013, 49, 1407-1412.	1.6	11
95	Socioeconomic and Disability Aspects. , 2013, , 653-658.		0
96	Improved precision of syndesmophyte measurement for the evaluation of ankylosing spondylitis using CT: a phantom and patient study. Physics in Medicine and Biology, 2012, 57, 4683-4704.	3.0	12
97	Economic Considerations of the Treatment of Ankylosing Spondylitis. American Journal of the Medical Sciences, 2012, 343, 371-374.	1.1	45
98	Sense of control and sociodemographic differences in self-reported health in older adults. Quality of Life Research, 2012, 21, 1509-1518.	3.1	25
99	Advances in the treatment of inflammatory arthritis. Best Practice and Research in Clinical Rheumatology, 2012, 26, 251-261.	3.3	46
100	Personalized Therapeutics: A Potential Threat to Health Equity. Journal of General Internal Medicine, 2012, 27, 868-870.	2.6	8
101	Concordance of sibling's recall of measures of childhood socioeconomic position. BMC Medical Research Methodology, 2011, 11, 147.	3.1	29
102	Sulfasalazine for the treatment of ankylosing spondylitis: Relic or niche medication?. Arthritis and Rheumatism, 2011, 63, 1472-1474.	6.7	1
103	Ankylosing Spondylitis: Patterns of Radiographic Involvement—A Re-examination of Accepted Principles in a Cohort of 769 Patients. Radiology, 2011, 258, 192-198.	7.3	87
104	The contribution of disease activity on functional limitations over time through psychological mediators: a 12-month longitudinal study in patients with ankylosing spondylitis. Rheumatology, 2011, 50, 2087-2092.	1.9	13
105	Medicare reimbursement and the use of biologic agents: Incentives, access, the public good, and optimal care. Arthritis Care and Research, 2010, 62, 293-295.	3.4	8
106	Trends in hospitalizations for Pneumocystis jirovecipneumonia among patients with rheumatoid arthritis in the US: 1996-2007. Arthritis and Rheumatism, 2010, 62, 3826-3827.	6.7	24
107	Association of measured physical performance and demographic and health characteristics with self-reported physical function: implications for the interpretation of self-reported limitations. Health and Quality of Life Outcomes, 2010, 8, 84.	2.4	25
108	Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nature Genetics, 2010, 42, 123-127.	21.4	573

#	Article	IF	Citations
109	Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Annals of the Rheumatic Diseases, 2010, 69, 868-871.	0.9	111
110	Access to Care and the Incidence of Endstage Renal Disease Due to Systemic Lupus Erythematosus. Journal of Rheumatology, 2010, 37, 1158-1163.	2.0	37
111	Psychological Correlates of Self-reported Disease Activity in Ankylosing Spondylitis. Journal of Rheumatology, 2010, 37, 829-834.	2.0	36
112	The JUPITER study: statins for the primary prevention of cardiovascular events in patients with inflammatory rheumatic diseases?. F1000 Medicine Reports, 2009, 1, 35.	2.9	3
113	Access to Care and the Incidence of End-Stage Renal Disease Due to Diabetes. Diabetes Care, 2009, 32, 1032-1036.	8.6	37
114	Time perspective and socioeconomic status: A link to socioeconomic disparities in health?. Social Science and Medicine, 2009, 68, 2145-2151.	3.8	125
115	RA treatment study group: Improvement in RA management. Joint Bone Spine, 2009, 76, 435-437.	1.6	5
116	Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis and Rheumatism, 2009, 61, 859-866.	6.7	113
117	Psychological correlates of self-reported functional limitation in patients with ankylosing spondylitis. Arthritis Research and Therapy, 2009, 11, R182.	3.5	51
118	Changes in the Incidence of Endstage Renal Disease Due to Lupus Nephritis in the United States, 1996–2004. Journal of Rheumatology, 2009, 36, 63-67.	2.0	109
119	Avoidable hospitalizations in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 59, 162-168.	6.7	47
120	Impact of ankylosing spondylitis on work and family life: Comparisons with the US population. Arthritis and Rheumatism, 2008, 59, 497-503.	6.7	67
121	Occupational physical activities and longâ€term functional and radiographic outcomes in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2008, 59, 822-832.	6.7	72
122	Interpreting studies of cardiovascular mortality in rheumatoid arthritis: The importance of timing. Arthritis and Rheumatism, 2008, 59, 1687-1689.	6.7	8
123	Computer Aided Evaluation of Ankylosing Spondylitis Using High-Resolution CT. IEEE Transactions on Medical Imaging, 2008, 27, 1252-1267.	8.9	33
124	Socioeconomic Status and the Incidence of ESRD. American Journal of Kidney Diseases, 2008, 51, 563-572.	1.9	118
125	Validation of English and Spanish-language versions of a screening questionnaire for rheumatoid arthritis in an underserved community. Journal of Rheumatology, 2008, 35, 1545-9.	2.0	7
126	Primer: measuring the effects of treatment in clinical trials. Nature Clinical Practice Rheumatology, 2007, 3, 291-297.	3.2	3

#	Article	IF	Citations
127	Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort. Annals of the Rheumatic Diseases, 2007, 66, 633-638.	0.9	225
128	Interpreting measurements of physical function in clinical trials. Annals of the Rheumatic Diseases, 2007, 66, iii32-iii34.	0.9	6
129	Laboratory Abnormalities at the Onset of Treatment of End-Stage Renal Disease. Archives of Internal Medicine, 2007, 167, 1083.	3.8	26
130	Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates obtained using hospitalization data. Arthritis and Rheumatism, 2007, 56, 2092-2094.	6.7	248
131	Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis. Journal of Rheumatology, 2007, 34, 2024-7.	2.0	29
132	Short-term prediction of mortality in patients with systemic lupus erythematosus: Classification of outcomes using random forests. Arthritis and Rheumatism, 2006, 55, 74-80.	6.7	78
133	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis and Rheumatism, 2006, 54, 2784-2792.	6.7	241
134	Defining remission in rheumatoid arthritis based on the Disease Activity Score 28. Nature Clinical Practice Rheumatology, 2006, 2, 124-125.	3.2	0
135	Social and Economic Consequences. , 2006, , 214-224.		5
136	Inter-hospital transfers of patients with systemic lupus erythematosus: characteristics, predictors, and outcomes. Journal of Rheumatology, 2006, 33, 1578-85.	2.0	4
137	Ethnic and socioeconomic disparities in health among patients with rheumatic disease. Current Opinion in Rheumatology, 2005, 17, 147-152.	4.3	44
138	Patient Participation in Medical Consultations. Medical Care, 2005, 43, 960-969.	2.4	476
139	Association between physician volume and in-hospital mortality in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2005, 52, 1646-1654.	6.7	37
140	Prospects for disease modification in ankylosing spondylitis: Do nonsteroidal antiinflammatory drugs do more than treat symptoms?. Arthritis and Rheumatism, 2005, 52, 1634-1636.	6.7	19
141	Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis and Rheumatism, 2005, 52, 2625-2636.	6.7	428
142	Risk factors for functional limitations in patients with longâ€standing ankylosing spondylitis. Arthritis and Rheumatism, 2005, 53, 710-717.	6.7	110
143	Severity of illness in patients with systemic lupus erythematosus hospitalized at academic medical centers. Journal of Rheumatology, 2005, 32, 27-33.	2.0	6
144	Decreases in rates of hospitalizations for manifestations of severe rheumatoid arthritis, 1983-2001. Arthritis and Rheumatism, 2004, 50, 1122-1131.	6.7	96

#	Article	IF	Citations
145	Rheumatology care, patient expectations, and the limits of time. Arthritis and Rheumatism, 2004, 51, 307-308.	6.7	11
146	Education level and mortality in systemic lupus erythematosus (SLE): Evidence of underascertainment of deaths due to SLE in ethnic minorities with low education levels. Arthritis and Rheumatism, 2004, 51, 616-624.	6.7	57
147	Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 50, 3170-3176.	6.7	41
148	Patient-centered care and health outcomes. Current Opinion in Rheumatology, 2004, 16, 89-90.	4.3	10
149	Outcome measurement: health status and quality of life. Current Opinion in Rheumatology, 2004, 16, 96-101.	4.3	28
150	Relative sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. Journal of Rheumatology, 2004, 31, 884-95.	2.0	24
151	Hospitalizations for coronary artery disease among patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 2519-2523.	6.7	42
152	Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 49, 810-818.	6.7	98
153	Clinical epidemiology: diagnostic and prognostic tests. Current Opinion in Rheumatology, 2003, 15, 104-109.	4.3	5
154	Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis and Rheumatism, 2002, 46, 223-231.	6.7	130
155	Medication toxicity among patients with ankylosing spondylitis. Arthritis and Rheumatism, 2002, 47, 234-241.	6.7	28
156	Hospital experience and mortality in patients with systemic lupus erythematosus: which patients benefit most from treatment at highly experienced hospitals?. Journal of Rheumatology, 2002, 29, 1198-206.	2.0	19
157	Predictors of the progression of functional disability in patients with ankylosing spondylitis. Journal of Rheumatology, 2002, 29, 1420-5.	2.0	88
158	Mortality and causes of death in systemic lupus erythematosus. Current Opinion in Rheumatology, 2001, 13, 345-351.	4.3	211
159	Recent improvements in survival in patients with rheumatoid arthritis: Better outcomes or different study designs?. Arthritis and Rheumatism, 2001, 44, 1467-1469.	6.7	67
160	Response criteria and criteria for clinically important improvement: Separate and equal?. Arthritis and Rheumatism, 2001, 44, 1728-1729.	6.7	7
161	Changes in the Incidence of End-stage Renal Disease Due to Lupus Nephritis, 1982-1995. Archives of Internal Medicine, 2000, 160, 3136.	3.8	81
162	Exercise and Changes in Health Status in Patients With Ankylosing Spondylitis. Archives of Internal Medicine, 2000, 160, 2969.	3.8	78

#	Article	IF	Citations
163	Identification of clinically important changes in health status using receiver operating characteristic curves. Journal of Clinical Epidemiology, 2000, 53, 279-284.	5.0	37
164	Cardiovascular and cerebrovascular morbidity and mortality among women with end-stage renal disease attributable to lupus nephritis. American Journal of Kidney Diseases, 2000, 36, 516-525.	1.9	55
165	Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 338-346.	6.7	462
166	Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. Arthritis and Rheumatism, 1999, 42, 780-789.	6.7	192
167	Hospital experience and mortality in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 891-898.	6.7	41
168	Health-related quality of life in ankylosing spondylitis: A survey of 175 patients. Arthritis and Rheumatism, 1999, 12, 247-255.	6.7	260
169	Treatments Used by Patients with Ankylosing Spondylitis Comparison with the Treatment Preferences of Rheumatologists. Journal of Clinical Rheumatology, 1999, 5, 1-8.	0.9	19
170	Pneumocystis carinii pneumonia in patients with connective tissue diseases: The role of hospital experience in diagnosis and mortality. Arthritis and Rheumatism, 1999, 42, 780.	6.7	2
171	QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS. Rheumatic Disease Clinics of North America, 1998, 24, 815-827.	1.9	93
172	Laboratory testing for systemic rheumatic diseases. Postgraduate Medicine, 1998, 103, 93-100.	2.0	28
173	Mortality Risks Associated With Specific Clinical Manifestations of Systemic Lupus Erythematosus. Archives of Internal Medicine, 1996, 156, 1337.	3.8	122
174	Patient education interventions in osteoarthritis and rheumatoid arthritis: A meta-analytic comparison with nonsteroidal antiinflammatory drug treatment. Arthritis and Rheumatism, 1996, 9, 292-301.	6.7	201
175	Long-term survival in systemic lupus erythematosus patient characteristics associated with poorer outcomes. Arthritis and Rheumatism, 1995, 38, 274-283.	6.7	228
176	Evaluative laboratory testing. Arthritis and Rheumatism, 1995, 38, 1555-1563.	6.7	13
177	Marital status and the progression of functional disability in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 581-588.	6.7	62
178	Reducing attrition bias with an instrumental variable in a regression model: Results from a panel of rheumatoid arthritis patients. Statistics in Medicine, 1993, 12, 1005-1018.	1.6	25
179	Clinical Prognostic Factors in Lupus Nephritis. Archives of Internal Medicine, 1992, 152, 2082.	3.8	125
180	Chylous ascites in cirrhosis: A case report and review of the literature. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 95-99.	2.8	27